IN2014DN08158A - - Google Patents
Info
- Publication number
- IN2014DN08158A IN2014DN08158A IN8158DEN2014A IN2014DN08158A IN 2014DN08158 A IN2014DN08158 A IN 2014DN08158A IN 8158DEN2014 A IN8158DEN2014 A IN 8158DEN2014A IN 2014DN08158 A IN2014DN08158 A IN 2014DN08158A
- Authority
- IN
- India
- Prior art keywords
- disclosed
- methods
- function
- specific inhibitor
- smad7 expression
- Prior art date
Links
- 101700026522 SMAD7 Proteins 0.000 abstract 2
- 102000049873 Smad7 Human genes 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 210000004153 islets of langerhan Anatomy 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 230000004083 survival effect Effects 0.000 abstract 1
- 238000002054 transplantation Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261625904P | 2012-04-18 | 2012-04-18 | |
| PCT/US2013/037150 WO2013158868A1 (en) | 2012-04-18 | 2013-04-18 | Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN08158A true IN2014DN08158A (enExample) | 2015-05-01 |
Family
ID=48326412
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN8158DEN2014 IN2014DN08158A (enExample) | 2012-04-18 | 2013-04-18 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US10081809B2 (enExample) |
| EP (1) | EP2839004B1 (enExample) |
| JP (2) | JP6348484B2 (enExample) |
| KR (1) | KR20150003824A (enExample) |
| CN (2) | CN104487574B (enExample) |
| AU (1) | AU2013249191B2 (enExample) |
| CA (1) | CA2870547A1 (enExample) |
| DK (1) | DK2839004T3 (enExample) |
| ES (1) | ES2732252T3 (enExample) |
| IN (1) | IN2014DN08158A (enExample) |
| MX (1) | MX370149B (enExample) |
| NZ (1) | NZ630914A (enExample) |
| RU (1) | RU2667960C2 (enExample) |
| WO (1) | WO2013158868A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITRM20030149A1 (it) | 2003-04-02 | 2004-10-03 | Giuliani Spa | Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico |
| JP5719776B2 (ja) | 2008-11-13 | 2015-05-20 | ノグラ ファーマ リミテッド | アンチセンス組成物およびその作製および使用 |
| WO2013037970A1 (en) | 2011-09-15 | 2013-03-21 | Nogra Pharma Limited | Methods for monitoring responsiveness to anti-smad7 therapy |
| NZ630914A (en) | 2012-04-18 | 2017-01-27 | Nogra Pharma Ltd | Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation |
| US10006029B2 (en) | 2013-03-15 | 2018-06-26 | Nogra Pharma Limited | Methods of treating colorectal cancer |
| EP2940115B1 (en) * | 2014-04-30 | 2018-10-17 | The Procter and Gamble Company | Cleaning composition |
| KR20170005058A (ko) | 2014-05-09 | 2017-01-11 | 노그라 파마 리미티드 | 염증성 장 질환을 치료하는 방법 |
| US10337004B2 (en) | 2014-10-17 | 2019-07-02 | Nogra Pharma Limited | Methods and compositions for treating a subject with a SMAD7 antisense oligonucleotide |
| ES2718380T3 (es) * | 2015-10-29 | 2019-07-01 | Procter & Gamble | Composición detergente líquida |
| EP3162878A1 (en) * | 2015-10-29 | 2017-05-03 | The Procter and Gamble Company | Liquid detergent composition |
| JP2019505598A (ja) | 2016-02-23 | 2019-02-28 | セルジーン アルパイン インベストメント カンパニー Ｉｉ， エルエルシー | Ｓｍａｄ７の阻害を用いて、腸線維症を治療する方法 |
| CN112840025A (zh) * | 2018-05-08 | 2021-05-25 | 迈阿密大学 | 用于将治疗性核酸递送到组织的材料方法 |
| KR20230031981A (ko) | 2019-05-14 | 2023-03-07 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| AU2021287998A1 (en) | 2020-06-11 | 2023-02-02 | Benaroya Research Institute At Virginia Mason | Methods and compositions for preventing type 1 diabetes |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6656475B1 (en) | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
| EP1456380B1 (en) * | 2001-11-02 | 2012-04-18 | Giuliani International Limited | Smad7 inhibitors for the treatment of cns diseases |
| ITRM20030149A1 (it) | 2003-04-02 | 2004-10-03 | Giuliani Spa | Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico |
| GB2417727B (en) | 2003-06-13 | 2008-01-16 | Alnylam Europe Ag | Double-stranded ribonucleic acid with increased effectiveness in an organism |
| ITRM20030393A1 (it) * | 2003-08-11 | 2005-02-12 | Giuliani Spa | Uso di oligonucleotidi (odn) antisenso per smad7 per il trattamento delle patologie mediate dal fattore di trascrizione nucleare nf-kb. |
| GB0326778D0 (en) * | 2003-11-18 | 2003-12-24 | Imp College Innovations Ltd | Biological materials and uses thereof |
| CA2580126C (en) | 2004-09-28 | 2014-08-26 | Quark Biotech, Inc. | Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases |
| RU2434942C2 (ru) * | 2004-09-28 | 2011-11-27 | Кварк Фармасьютикалс, Инк. | Олигорибонуклеотиды и способы их применения для лечения острой почечной недостаточности и других заболеваний |
| WO2007039151A1 (en) * | 2005-09-28 | 2007-04-12 | Universität Zürich | Blockers of transforming growth factor beta and its receptors for the treatment of infectious diseases |
| CA2720675C (en) * | 2008-04-18 | 2019-08-27 | Baxter International Inc. | Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes |
| JP5719776B2 (ja) | 2008-11-13 | 2015-05-20 | ノグラ ファーマ リミテッド | アンチセンス組成物およびその作製および使用 |
| WO2013037970A1 (en) | 2011-09-15 | 2013-03-21 | Nogra Pharma Limited | Methods for monitoring responsiveness to anti-smad7 therapy |
| NZ630914A (en) | 2012-04-18 | 2017-01-27 | Nogra Pharma Ltd | Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation |
| JP6502863B2 (ja) | 2013-03-15 | 2019-04-17 | ノグラ ファーマ リミテッド | 結腸直腸癌を処置する方法 |
| US10006029B2 (en) | 2013-03-15 | 2018-06-26 | Nogra Pharma Limited | Methods of treating colorectal cancer |
| KR20170005058A (ko) | 2014-05-09 | 2017-01-11 | 노그라 파마 리미티드 | 염증성 장 질환을 치료하는 방법 |
| US20170233736A1 (en) | 2014-10-17 | 2017-08-17 | Nogra Pharma Limited | Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels |
| US10337004B2 (en) | 2014-10-17 | 2019-07-02 | Nogra Pharma Limited | Methods and compositions for treating a subject with a SMAD7 antisense oligonucleotide |
| EP3355896A2 (en) | 2015-09-30 | 2018-08-08 | Nogra Pharma Limited | Methods of using smad7 antisense oligonucleotides based on biomarker expression |
| WO2017144689A1 (en) | 2016-02-24 | 2017-08-31 | Nogra Pharma Limited | Methods of treating celiac disease using smad7 inhibition |
| WO2018122376A1 (en) | 2016-12-30 | 2018-07-05 | Nogra Pharma Limited | Compositions of smad7 antisense oligonucleotide and methods of treating or preventing psoriasis |
-
2013
- 2013-04-18 NZ NZ630914A patent/NZ630914A/en not_active IP Right Cessation
- 2013-04-18 EP EP13721452.4A patent/EP2839004B1/en active Active
- 2013-04-18 JP JP2015507173A patent/JP6348484B2/ja not_active Expired - Fee Related
- 2013-04-18 CN CN201380020520.2A patent/CN104487574B/zh not_active Expired - Fee Related
- 2013-04-18 MX MX2014012650A patent/MX370149B/es active IP Right Grant
- 2013-04-18 CA CA2870547A patent/CA2870547A1/en not_active Abandoned
- 2013-04-18 ES ES13721452T patent/ES2732252T3/es active Active
- 2013-04-18 KR KR1020147032172A patent/KR20150003824A/ko not_active Abandoned
- 2013-04-18 IN IN8158DEN2014 patent/IN2014DN08158A/en unknown
- 2013-04-18 AU AU2013249191A patent/AU2013249191B2/en not_active Ceased
- 2013-04-18 CN CN201710440085.9A patent/CN107252492A/zh active Pending
- 2013-04-18 DK DK13721452.4T patent/DK2839004T3/da active
- 2013-04-18 WO PCT/US2013/037150 patent/WO2013158868A1/en not_active Ceased
- 2013-04-18 RU RU2014146170A patent/RU2667960C2/ru not_active IP Right Cessation
- 2013-04-18 US US14/394,999 patent/US10081809B2/en not_active Expired - Fee Related
-
2018
- 2018-05-31 JP JP2018104372A patent/JP2018131468A/ja active Pending
- 2018-08-10 US US16/100,906 patent/US10443056B2/en not_active Expired - Fee Related
-
2019
- 2019-09-04 US US16/559,974 patent/US20200239884A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20150003824A (ko) | 2015-01-09 |
| US20150315573A1 (en) | 2015-11-05 |
| JP2015514778A (ja) | 2015-05-21 |
| EP2839004A1 (en) | 2015-02-25 |
| AU2013249191B2 (en) | 2019-01-03 |
| MX370149B (es) | 2019-12-03 |
| US10443056B2 (en) | 2019-10-15 |
| CN104487574A (zh) | 2015-04-01 |
| DK2839004T3 (da) | 2019-07-01 |
| WO2013158868A1 (en) | 2013-10-24 |
| JP6348484B2 (ja) | 2018-06-27 |
| JP2018131468A (ja) | 2018-08-23 |
| CN107252492A (zh) | 2017-10-17 |
| HK1207117A1 (en) | 2016-01-22 |
| US10081809B2 (en) | 2018-09-25 |
| RU2667960C2 (ru) | 2018-09-25 |
| EP2839004B1 (en) | 2019-06-12 |
| NZ630914A (en) | 2017-01-27 |
| US20190136237A1 (en) | 2019-05-09 |
| CN104487574B (zh) | 2017-07-07 |
| MX2014012650A (es) | 2015-04-08 |
| AU2013249191A1 (en) | 2014-10-09 |
| RU2014146170A (ru) | 2016-06-10 |
| CA2870547A1 (en) | 2013-10-24 |
| US20200239884A1 (en) | 2020-07-30 |
| ES2732252T3 (es) | 2019-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN08158A (enExample) | ||
| PH12019502292A1 (en) | Methods and compositions for treatment of a genetic condition | |
| UA118328C2 (uk) | Спосіб інтегрування екзогенних послідовностей у геном рослинної клітини | |
| SG10201906304TA (en) | Use of perfusion decellularized liver for islet cell recellularization | |
| MX371176B (es) | Cartuchos de fibra hueca y componentes y métodos para su construcción. | |
| PH12014501429A1 (en) | Differentiation of human embryonic stem cells into single hormonal insulin positive cells | |
| PH12013500349A1 (en) | Differentiation of pluripotent stem cells | |
| IL221481A (en) | A method for efficiently determining induced multi-potential stem cells | |
| PH12013500827A1 (en) | Chromobacterium bioactive compositions and metabolites | |
| PH12014502588A1 (en) | Catechol o-methyltransferase activity inhibiting compounds | |
| JO3450B1 (ar) | أشكال جرعات تحرير جديدة معدلة لمثبطات زانثين اوكسيدوريدوكتيز أو مثبطات زانثين اوكسيديز | |
| SG11201505965TA (en) | Culture method for stable undifferentiated proliferation of pluripotent stem cells | |
| IN2014DN11201A (enExample) | ||
| MX2014013752A (es) | Inhibidores de nampt. | |
| PH12014502513A1 (en) | Nampt inhibitors | |
| MX348311B (es) | Inhibidores nampt. | |
| IL240934A0 (en) | A method of treating pancreatic and liver conditions by transplanting stem cells into the walls of the bile duct | |
| MX2021000332A (es) | Metodos para tratar rechazo mediado por anticuerpos en pacientes de trasplante de organos con inhibidor de c1-esterasa. | |
| MX2013006165A (es) | Fibras de degradacion controlada. | |
| SG11201408717XA (en) | Stem cells and pancreatic cells useful for the treatment of insulin-dependent diabetes mellitus | |
| MX393754B (es) | Metodos y composiciones para inhibir cnksr1 | |
| MX2010007945A (es) | Preparacion y transplante de celulas de isletas pancreaticas. | |
| EA201590551A1 (ru) | Способы ингибирования роста волос | |
| IL213629A0 (en) | Apparatus and method for the preservation of pancreatic tissue and islet cells for transplantation | |
| IN2014CN02585A (enExample) |